MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-03-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tolerability pharmacokineticssafety tolerabilitytumorcarcinomapd
  Phrases that lowered it: participantssolidopen labelimmunogenicitynsclc
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Maximum age: 101 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 5.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Number of arms: 11 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 32 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past termination rate: 8.5% (raises risk) · Sponsor's track record
• Sponsor's past trials: 142 (lowers risk) · Sponsor's track record
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1/2 Study to Evaluate MEDI4736 NCT01693562 · started 2012 · scored riskier than 82% of active trials completed
• A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors NCT02221960 · started 2014 · scored riskier than 10% of active trials completed
• A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours NCT01938612 · started 2013 · scored riskier than 40% of active trials completed
• A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors NCT02318394 · started 2015 · scored riskier than 33% of active trials completed
• A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies NCT02205333 · started 2014 · scored riskier than 34% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.